O
Oligon Therapeutics
Multimodal RNA therapeutics silencing multiple disease targets
About Oligon Therapeutics
Oligon Therapeutics is a biotechnology company pioneering a novel class of RNA-based, multi-targeting drugs for oncology, immunology, and other complex diseases. The company was launched on September 23, 2025, with an initial commitment of US $14 million from a consortium of investors including CTI Life Sciences Fund (CTI), the Fonds de solidarité FTQ, and Investissement Québec (IQ). Operations are based in Montreal, Quebec, leveraging the region's life sciences and AI research ecosystem.
The company was founded by Dr. Spyro Mousses, who serves as the CEO. The leadership team also includes Dr. David Bouffard as Chief Operating Officer, Dr. David Azorsa as Chief Scientific Officer, and Dr. Jeff Kiefer as Chief Technology Officer. The company's core technology is the proprietary SeekR™ platform, which engineers and produces self-delivering, multimodal RNA therapeutics. These therapeutics, administered as injectables without special formulations, integrate dual RNA aptamers (oligo-binders) and dual siRNA silencers into a single molecule. This structure allows for unprecedented precision by targeting two specific cell surface receptors, triggering efficient cellular uptake and simultaneously silencing multiple disease-related genes.
Oligon's business model is focused on developing its own pipeline of therapeutic programs and partnering with biopharma and academic collaborators. The current internal pipeline includes programs aimed at cancer immunotherapy by reversing T-cell exhaustion and reprogramming pathogenic T-cell subtypes in immunology and inflammation. Its partnered programs are primarily focused on different types of cancer, with a strategy to expand into additional indications through further industry collaboration. By designing therapies that can deliver siRNA to various cell types beyond the liver, a limitation of previous RNAi drugs, Oligon aims to unlock the full potential of RNA interference in treating complex, multigenic diseases.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2025 | $14M | $56M | Invest Quebec · Fonds de solidarité FTQ · CTI Life Sciences | ↗ |
Growth signals
Latest recorded traffic for Oligon Therapeutics is 1.4K monthly website visits, down 30% over the last three months. Oligon Therapeutics's team grew 250% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Tychobio.aiAI platform for designing RNA-based therapies. |
Saint-Mandé, France | Operational | 5 | — | — |
JAMA TxExosome-based therapeutics for cardiogenetic diseases |
Utrecht, Netherlands | Operational | |||
| New York City, United States | Operational | ||||
ReThink64 BionetworksIntercellular router system for large-molecule drug delivery |
Fremont, United States | Operational | |||
Therna BiosciencesAI-powered platform designing programmable RNA medicines |
San Carlos, United States | Operational | |||
Vivatides TherapeuticsNext-generation, extra-hepatic targeted RNA therapeutics |
Woburn, United States | Operational | |||
falcon-hd.comOral RNA splicing modifiers targeting genetic diseases like Huntington's by modulating protein expression and slowing disease progression |
— | Operational | |||
| China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Oligon Therapeutics in the Montreal ecosystem
The Oligon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Invest Quebec
Fonds de solidarité FTQ
CTI Life Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oligon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oligon Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







